[CAS NO. 1402438-74-7] PF-06273340

Name: PF-06273340
Brand: Arctom Scientific
SKU: SLK-S8407

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1402438-74-7]

Store

Catalog

SLK-S8407

Brand

Selleck

CAS

1402438-74-7

DESCRIPTION [1402438-74-7]

Overview

MDL	-
Molecular Weight	479.92
Molecular Formula	C23H22ClN7O3
SMILES	-

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.0837 mL	10.4184 mL	20.8368 mL
5 mM	0.4167 mL	2.0837 mL	4.1674 mL
10 mM	0.2084 mL	1.0418 mL	2.0837 mL
50 mM	0.0417 mL	0.2084 mL	0.4167 mL

Description

PF-06273340 is a highly potent, kinases elective, well-tolerated inhibitor with values of 6, 4, 3 nM for TrkA, TrkB, Trk C, respectively.

Targets

TrkC ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)
3 nM	4 nM	6 nM

In vitro

PF-06273340 is a highly potent pan-Trk inhibitor, with an excellent LipE profile. PF-06273340 is profiled in a series of in vitro safety assays, showing little cytotoxicity in THLE or HepG2 cell lines (IC50 > 42 μM and >300 μM, respectively). In this broad panel, all IC50/Ki values were >10 μM except for COX-1 (IC50 = 2.7 μM) and dopamine transporter assays (Ki = 5.2 μM) and PDEs 4D, 5A, 7B, 8B, and 11 (54−89% inhibition at 10 μM). PF-06273340 is screened in the Invitrogen wide kinase panel of 309 kinases, and all were inhibited by <40% when tested at 1 μM except the following: MUSK (IC50 53 nM), FLT-3 (IC50 395 nM), IRAK1 (IC50 2.5 μM), MKK (90% @ 1 μM), and DDR1 (60% @ 1 μM).

In vivo

In rats, decreases in white blood cell count are observed from 150 mg/kg/day. At doses ≥250 mg/kg, increases in body weight gain and food consumption are observed, effects that could be rationalized as being mediated by central inhibition of TrkB, agonists of which are known to be anorexigenic in rodents. Adaptive changes in the liver are observed microscopically and accompanied by increased liver weight at ≥250 mg/kg and increases cholesterol at 1000 mg/kg. Overall, PF-06273340 is well tolerated up to 1000 mg/kg/day where plasma exposure (unbound Cavg) is approximately 400×TrkA IC50.

References

[1] Skerratt SE, et al. J Med Chem. 2016, 59(22):10084-10099.